https://www.wsj.com/articles/behind-israels-swift-rollout-of-covid-19-vaccine-boosters-11632821987
By getting early access to Pfizer’s vaccine, Israeli scientists had more and earlier data than their counterparts elsewhere—and were willing to act on it
TEL AVIV—In late July, dozens of Israeli scientists and government health officials were locked in a marathon video call where they examined new data indicating that the effectiveness of the Covid vaccine developed by Pfizer Inc. and BioNTech SE was waning.
Infections from the new Delta variant were increasing, and growing numbers of people were falling seriously ill, even those who had had both shots of the vaccine. Lives were potentially on the line.
Within days of the midnight vote that decided to distribute a third shot, the first of millions of booster shots were administered, months before the U.S. or any other country would take the same step.
“It was a really tough discussion,” said epidemiologist Gili Regev-Yochay, who presented key research on the effectiveness of booster shots. “[But] it was a decision that was reached essentially with one voice.”
Throughout the global effort against Covid-19, Israel’s public health experts have been consistently ahead of their counterparts elsewhere in the world. By securing an early supply deal with Pfizer for its vaccine, sweetened in part by a promise to share data from Israel’s extensive network of health maintenance organizations, they have had an edge in understanding how the vaccine behaves in the real world.